Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 891 to 900 of 1543 total matches.

In Brief: Esomeprazole Strontium

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
® Vol. 56 (1447) July 21, 2014 Aciphex Dexilant Dexlansoprazole esomeprazole strontium GERD lansoprazole ...
The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium): treatment of gastroesophageal reflux disease (GERD), prevention of NSAID-induced gastric ulcers, eradication of Helicobacter pylori, and treatment of pathological hypersecretory conditions. It was first marketed in December 2013 as a branded drug (Esomeprazole Strontium) and a month later as a generic drug.Strontium is incorporated into bone. It is not recommended for use in children or during pregnancy because of the absence of safety data...
Med Lett Drugs Ther. 2014 Jul 21;56(1447):64 |  Show IntroductionHide Introduction

Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
. ©2015. www.fdbhealth.com/policies/drug-pricing-policy. 101 The Medical Letter ® Vol. 57 (1472) July 6 ...
The FDA has approved a new IV formulation of dantrolene (Ryanodex – Eagle) for prevention and treatment of malignant hyperthermia in adults and children. The new formulation requires fewer vials, less fluid volume, and less time for preparation and administration than other available IV dantrolene products (Dantrium, Revonto).
Med Lett Drugs Ther. 2015 Jul 6;57(1472):100 |  Show IntroductionHide Introduction

In Brief: New Warnings for Janus Kinase Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
September 15, 2021. 161 The Medical Letter ® Vol. 63 (1634) October 4, 2021 upadacitinib tofacitinib ...
The FDA has required updates to the boxed warnings in the labeling of the Janus kinase (JAK) inhibitors tofacitinib (Xeljanz, Xeljanz XR), baricitinib (Olumiant), and upadacitinib (Rinvoq) describing increased risks of major adverse cardiovascular events, malignancy, thrombosis, and death with their use. The new warnings were prompted by the results of a postmarketing safety trial with tofacitinib and were added to the labels of baricitinib and upadacitinib based on the presumption of a class effect. The tofacitinib package insert had contained a boxed warning about an increased...
Med Lett Drugs Ther. 2021 Oct 4;63(1634):160 |  Show IntroductionHide Introduction

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
/policies/drug-pricing-policy. The Medical Letter ® Vol. 65 (1668) January 23, 2023 Furoscix furosemide ...
The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5   doi:10.58347/tml.2023.1668d |  Show IntroductionHide Introduction

In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
(AL, IN, SC, and WA) restrict interchangeability entirely.4 The Medical Letter ® Vol. 65 (1673 ...
Insulin glargine-aglr (Rezvoglar – Lilly), which was approved by the FDA as a biosimilar to the reference product Lantus in 2021 and received interchangeability status with Lantus in 2022, will become available in the US on April 1, 2023. It is the second biosimilar insulin product to be designated as interchangeable with Lantus; Semglee was the first. Rezvoglar did not receive interchangeability status with Lantus at the time of its initial approval because the manufacturer of Semglee had exclusivity for 12 months.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):56   doi:10.58347/tml.2023.1673c |  Show IntroductionHide Introduction

In Brief: Alternatives to Mifepristone for Medication Abortion

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
duration of ≤63 days’ gestation, a regimen consisting of a single intramuscular The Medical Letter ® Vol ...
The possibility that use of mifepristone (Mifeprex, and generics) may be restricted has led to questions about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3   doi:10.58347/tml.2023.1679d |  Show IntroductionHide Introduction

Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
® Vol. 65 Published online August 21, 2023 metformin liraglutide type 2 diabetes empagliflozin Bydureon ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone (Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e137   doi:10.58347/tml.2023.1683e |  Show IntroductionHide Introduction

In Brief: Anktiva for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
. All patients e106 The Medical Letter ® Vol. 66 Published online June 24, 2024 1. In brief: Adstiladrin ...
Nogapendekin alfa inbakicept-pmln (Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6   doi:10.58347/tml.2024.1705e |  Show IntroductionHide Introduction

Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004  (Issue 1179)
, New Rochelle, NY 10801 A Nonprofit Publication Vol. 46 (Issue 1179) March 29, 2004 Also ...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and...
Med Lett Drugs Ther. 2004 Mar 29;46(1179):27-8 |  Show IntroductionHide Introduction

Clobetasol Propionate (Clobex) Spray for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006  (Issue 1231)
March 27 Topical steroid topical steroids Treatment of psoriasis Ultravate Vanos vol 48 vol. 48 volume ...
The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% (Clobex - Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol propionate is also available as a cream, ointment, gel, solution, foam, lotion and shampoo.
Med Lett Drugs Ther. 2006 Mar 27;48(1231):27-8 |  Show IntroductionHide Introduction